Eagan, Minnesota--(Newsfile Corp. - January 25, 2024) - Dynatronics Corporation (NASDAQ: DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that the company will release financial results for its second quarter of fiscal year 2024 ended December 31, 2023 on Thursday, February 8, 2024 before the market opens.
The company will subsequently hold a conference call, consisting of prepared remarks by management, and a question-and-answer session with analysts, at 8:00 AM ET on Thursday, February 8, 2024, to review its second quarter fiscal year 2024 results.
Interested persons may access the live conference call by dialing 1-800-319-4610 (U.S./Canada callers) or +1-604-638-5340 (international callers). It is recommended that participants call or login 10 minutes ahead of the scheduled start time to ensure proper connection. An audio replay will be available one hour after the live call until Midnight on February 15, 2024, by dialing 1-855-669-9658 (U.S./Canada callers) or +1-604-674-8052 (international callers), using replay access code 0667.
About Dynatronics Corporation
Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Contact:
Dynatronics Corporation
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
For additional information, please visit: www.dynatronics.com
Connect with Dynatronics on LinkedIn
| Last Trade: | US$0.10 |
| Daily Change: | -0.006 -5.66 |
| Daily Volume: | 9,496 |
| Market Cap: | US$726K |
February 08, 2024 January 15, 2024 November 09, 2023 October 30, 2023 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
